Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

scientific article published on 26 September 2007

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00280-007-0603-8
P698PubMed publication ID17899082

P50authorJan H BeumerQ49531403
Timothy SynoldQ78536675
Heinz-Josef LenzQ89668545
P2093author name stringJames H Doroshow
Merrill J Egorin
Edward M Newman
Robert A Parise
P433issue2
P921main subjectcytotoxicityQ246181
P304page(s)363-368
P577publication date2007-09-26
P1433published inCancer Chemotherapy and PharmacologyQ326137
P1476titleConcentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)
P478volume62

Reverse relations

cites work (P2860)
Q37254998A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer
Q35130668A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine
Q34168766Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia
Q58617093Biodistribution, tumor detection and radiation dosimetry of F-18 5-Fluoro-2'-Deoxycytidine (F-FdCyd) with Tetrahydrouridine in solid tumors
Q37851012Cancer epigenetics reaches mainstream oncology
Q36599581Chromatin deregulation in disease.
Q61446834Clinicopathological and prognostic significance of hypermethylation in hepatocellular carcinoma: a meta-analysis
Q26783596Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review
Q34972245DNA demethylating antineoplastic strategies: a comparative point of view
Q36986433DNA methylation: its role in cancer development and therapy
Q37602208DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.
Q37701947Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?
Q36523796Digging deep into "dirty" drugs - modulation of the methylation machinery
Q35750354Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
Q37962013Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers
Q26828724Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments
Q35162148Epigenetic therapy for breast cancer
Q37964702Epigenetic-based therapies in cancer: progress to date
Q39358434HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276).
Q84325850Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase
Q36706248Improving nucleoside analogs via lipid conjugation: Is fatter any better?
Q36589313Inhibition of cancer cell proliferation by 5-fluoro-2'-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway
Q38838257LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.
Q34324930Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine
Q38240032Oncometabolites-driven tumorigenesis: From genetics to targeted therapy
Q36070627Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans
Q26751251Orchestrating epigenetic roles targeting ocular tumors
Q34195332Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Q36480084Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors
Q37962596Promises and challenges of anticancer drugs that target the epigenome
Q33773171Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination
Q46417113Synthesis and antiproliferative activities of 5-azacytidine analogues in human leukemia cells
Q55435258Targeting DNA Methyltranferases in Urological Tumors.
Q37320354Targeting DNA methylation
Q34258037Targeting DNA methylation for epigenetic therapy
Q26778508The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review
Q38119782The promise and failures of epigenetic therapies for cancer treatment
Q38257126Translational research in oncology--10 years of progress and future prospects

Search more.